Double Blind Bio
Double Blind Bio builds agentic AI infrastructure that automates site identification, feasibility, study startup, and trial execution workflows for biotech and pharma sponsors and clinical research sites. Founded 2025, headquartered in San Francisco, backed by Define Ventures, SignalFire, and Peterson Ventures.
- Company typePrivate
- Founded2025
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Double Blind Bio does
Double Blind Bio (legal entity Double Blind Bio, Inc., Delaware corporation) builds agentic AI infrastructure for clinical trial workflows, serving both trial sponsors (biotech and pharma companies, plus Contract Research Organizations) and clinical research sites. The platform deploys AI agents that automate work across the trial lifecycle — site identification, feasibility processing, study startup, ongoing trial engagement, and post-award monitoring — functioning inside existing sponsor and site systems rather than as standalone tools. The product is modular: sponsors use Site Selection + Feasibility, Study Startup, and Site Engagement modules, while sites use a Growth Module (trial discovery), Form Automation (AI pre-fill of feasibility responses), Mission Control (overnight monitoring of SUSARs, amendments, visit windows, and expiring approvals), and an AI-Powered Intelligent Assistant for BD outreach. All modules are anchored on a curated, dynamically updated database of clinical trial sites with advanced filtering on therapeutic area, experience, geographic reach, patient population, and historical performance.
The company operates a B2B SaaS model with annual subscription pricing (not publicly disclosed), accessed through a demo-based enterprise sales motion targeting both sponsor-side biotech/pharma teams and site-side clinical research organizations. Distribution is direct enterprise sales combined with inside sales for mid-market accounts, supported by content marketing via a company blog and product pages. The company sells to two primary buyer personas — life sciences companies (biotech/pharma) seeking faster site selection and activation without headcount additions, and clinical research sites seeking faster trial discovery and lower administrative burden on BD and feasibility teams. CROs are identified as a secondary segment.
Founded in 2025 and headquartered in San Francisco, Double Blind Bio is led by CEO and co-founder Shruti Tibrewala (previously at Flatiron Health and Novartis; Stanford B.S., Berkeley MBA/MPH) and CTO and co-founder Dave Hughes. The team draws from Google, Verily, Flatiron Health, and Stanford. The company is venture-backed by Define Ventures, SignalFire, and Peterson Ventures, having raised approximately $5.6 million as of December 2025, and was named one of 10 AI-based pharmaceutical startups to watch in 2026 by StartUs Insights. The operating footprint extends to U.S. and international customers per the company's terms of service.
Double Blind Bio firmographics
Firmographics- Name
- Double Blind Bio
- Legal name
- Double Blind Bio, Inc.
- Website
- https://doubleblindbio.co
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Double Blind Bio builds agentic AI infrastructure that automates site identification, feasibility, study startup, and trial execution workflows for biotech and pharma sponsors and clinical research sites. Founded 2025, headquartered in San Francisco, backed by Define Ventures, SignalFire, and Peterson Ventures.
- Ownership category
- akta.pro rank
Double Blind Bio industry classification
Industry- Product category
- Clinical Trial Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
- akta.pro secondary industries
- Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where Double Blind Bio is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Double Blind Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- SaaS Subscription: Software-as-a-service platform with subscription-based access to AI agents for clinical trial site selection, feasibility automation, and business development. Organizations pay recurring fees for access to the platform, database, and AI-powered tools. Subscription automatically renews at end of each billing period unless cancelled.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Subscription-based SaaS with organization-level access |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Double Blind Bio product offering
Product offeringCore offering
Double Blind Bio provides an AI-powered agentic infrastructure platform that automates clinical trial workflows for both sponsors and sites. The platform deploys AI agents that handle site selection, feasibility response generation, study startup, document routing, and ongoing trial execution. Sponsors use modules including Site Selection + Feasibility, Study Startup, and Site Engagement; sites use the Growth Module, Form Automation, and Mission Control, all backed by a curated, dynamically updated clinical research site database.
Product overview
Double Blind Bio offers a unified agentic infrastructure platform for clinical trials, combining AI agents that automate workflows across the trial lifecycle. The platform serves both sponsors (biotech, pharma, CROs) and clinical research sites through interconnected modules. For sponsors: Site Selection + Feasibility, Study Startup, and Site Engagement modules. For sites: Growth Module, Form Automation, and Mission Control. The AI-Powered Intelligent Assistant connects both audiences. All modules share a curated site database and compound intelligence across trials.
Differentiator
Problem solved
Functional benefit
Products and services
- Agentic Infrastructure Platform
Quantifiable outcome
- Sites save 5+ hours every week by reducing manual sponsor outreach, feasibility, and startup admin
- +4 more outcomes
Companies that use Double Blind Bio
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Double Blind Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature10 records
Double Blind Bio partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights5 records
Double Blind Bio competitors and assessment
Company assessmentDirect peers
- Deep 6 AI: AI-powered clinical trial patient and site matching platform that mines EHR data to accelerate trial recruitment and feasibility. Targets the same sponsor and site workflows as Double Blind Bio.
- Trial Library: Site identification and feasibility platform helping sponsors find the right investigative sites. Closely overlaps with Double Blind Bio's Site Selection + Feasibility module.
- Medable: Decentralized clinical trial technology platform serving sponsors and sites with digital trial infrastructure. Adjacent overlap with DBB on trial startup automation and site workflow tools.
- Mendel: AI platform purpose-built for clinical trial operations, including site feasibility, study design, and patient cohort identification. Directly comparable to Double Blind Bio in applying AI agents to clinical trial workflows.
Broad incumbents
- Veeva Systems: Public, large-scale provider of cloud software for life sciences including Veeva Vault CTMS for clinical trial management. Represents the incumbent platform that DBB must displace or integrate with.
- IQVIA: Largest global CRO with extensive clinical trial technology, including AI-driven site identification and feasibility tools. The dominant incumbent that DBB competes against for sponsor mindshare.
- Medidata (Dassault Systèmes): Major clinical trial technology platform (Rave EDC, eCOA, RTSM) serving pharma sponsors and CROs. Broad incumbent with overlapping capabilities in clinical trial operations and site workflows.
Emerging players
- Antidote: Clinical trial matching and recruitment platform using structured data to connect patients and sites with relevant trials. Overlaps with DBB's Growth Module and site-discovery capabilities.
- Paradigm Health: Tech-enabled clinical trial site network focused on bringing modern infrastructure to under-served patient populations. Potential partner/competitor at the site-network layer where DBB also operates.
- TrialSpark (now Tempus Clinical): Tech-forward clinical trial operations platform (acquired by Tempus) that modernizes trial execution including site activation and study startup. Directly comparable in automating startup workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Double Blind Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Double Blind Bio leadership team
Management profileNumber of profiles
Profiles10 records
Double Blind Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Double Blind Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Double Blind Bio
What does Double Blind Bio do?
Double Blind Bio provides an AI-powered agentic infrastructure platform that automates clinical trial workflows for both sponsors and sites. The platform deploys AI agents that handle site selection, feasibility response generation, study startup, document routing, and ongoing trial execution. Sponsors use modules including Site Selection + Feasibility, Study Startup, and Site Engagement; sites use the Growth Module, Form Automation, and Mission Control, all backed by a curated, dynamically updated clinical research site database.
Is Double Blind Bio a public or private company?
Double Blind Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Double Blind Bio founded?
Double Blind Bio was founded in 2025. It employs 1 to 10 people.
Where is Double Blind Bio based?
Double Blind Bio is headquartered in San Francisco, United States, in the North America region.
How does Double Blind Bio make money?
One revenue line is on record: saaS Subscription.
Who are Double Blind Bio's main competitors?
Direct peers on record are Deep 6 AI, Trial Library, Medable and Mendel. Broad incumbents are Veeva Systems, IQVIA and Medidata (Dassault Systèmes). Emerging players are Antidote, Paradigm Health and TrialSpark (now Tempus Clinical).
Does Double Blind Bio have an API?
No public API is recorded for Double Blind Bio.
What industry is Double Blind Bio in?
Double Blind Bio's product category is Clinical Trial Software. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLAGACAC, Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts). Its NAICS code is 5132 and its SIC code is 8731.